Evidence map›Paper›PMID 43005920›Full record

ReviewClinical and experimental hepatology2026

Dietary interventions in metabolic dysfunction-associated steatotic liver disease: current evidence, research priorities, and clinical translation.

Anna Choręziak, Piotr Rzymski, Barbara Poniedziałek, Krystyna Dobrowolska, Michał Brzdęk, Jerzy Jaroszewicz, Dorota Zarębska-Michaluk

Abstract readReview
In one paragraph

Review in Clinical and experimental hepatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Anna ChoręziakDepartment of Environmental Medicine, Poznan University of Medical Sciences, Poznan, Poland.
Piotr RzymskiDepartment of Environmental Medicine, Poznan University of Medical Sciences, Poznan, Poland.
Barbara PoniedziałekDepartment of Environmental Medicine, Poznan University of Medical Sciences, Poznan, Poland.
Krystyna DobrowolskaCollegium Medicum of Jan Kochanowski University, Kielce, Poland.
Michał BrzdękCollegium Medicum of Jan Kochanowski University, Kielce, Poland.
Jerzy JaroszewiczDepartment of Infectious Diseases and Hepatology, Medical University of Silesia, Katowice, Poland.
Dorota Zarębska-MichalukCollegium Medicum of Jan Kochanowski University, Kielce, Poland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Metabolic dysfunction-associated steatotic liver disease (MASLD) is closely linked to excess adiposity, insulin resistance, and adverse dietary patterns. Dietary management is a potentially disease-modifying component of care, but no single standardized "MASLD diet" applies to all patients. This narrative review evaluates energy restriction, Mediterranean-style eating, low-carbohydrate, ketogenic, dietary approaches to stop hypertension (DASH), intermittent fasting, vegetarian, and plant-based approaches, together with practical food-based recommendations. The strongest evidence supports improved dietary quality and, in patients with excess body weight, a sustainable energy deficit that produces clinically meaningful weight loss. Mediterranean-style eating remains the best-supported named pattern, although evidence is stronger for liver fat and cardiometabolic outcomes than for histological or clinical liver outcomes. Management should prioritize minimally processed, predominantly plant-based, fiber-rich foods and unsaturated fats while limiting sugar-sweetened beverages, refined carbohydrates, ultra-processed foods, red and processed meat, and alcohol. Normal-weight MASLD, cirrhosis, and incretin-associated weight loss require individualized goals emphasizing metabolic control, nutritional adequacy, and muscle preservation.

Indexed as

dietary interventionshepatologyMediterranean dietmetabolic dysfunction-associated steatotic liver diseasenutrition

Identifiers

PMID43005920
PMCPMC13746859

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.